Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term EGFR. Found 11 abstracts

Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang LS, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ. A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):609-13.   PMCID: NIH funded - needs PMCID
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research. 2009 Apr;69(7):3021-31.   PMCID: PMCID: PMC2871252
Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone. Clinical Colorectal Cancer. 2008 May;7(3):184-90.
Psyrri A, Egleston B, Weinberger P, Yu ZW, Kowalski D, Sasaki C, Haffty B, Rimm D, Burtness B. Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiology Biomarkers & Prevention. 2008 Jun;17(6):1486-92.
Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, Nilsson FY, Stahl S, Glimelius B, Carlsson J. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nuclear Medicine and Biology. 2007 Aug;34(6):609-18.
Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl CD, Kim SH, Klein-Szanto A, Diehl JA, Herlyn M, El-Deiry W, Rustgi AK. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene. 2007 Apr;26(16):2353-64.
Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Current Cancer Drug Targets. 2006 Dec;6(8):691-710.
Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. INTERNATIONAL JOURNAL OF ONCOLOGY. 2006 Nov;29(5):1237-46.
Cohen SJ, Meropol NJ. Drug development in pancreatic cancer - Finally, biology begets therapy. International Journal of Gastrointestinal Cancer. 2002 Jan;32(2-3):91-106.
Abdollahi A, Bao R, Hamilton TC. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene. 1999 Nov 11;18(47):6477-87.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term EGFR

EGFR tyrosine kinase inhibitor LUNG-CANCER GROWTH-FACTOR-RECEPTOR GENE COPY NUMBER ACTIVATION PHASE-II MULTICENTER CANCER human-breast-cancer cetuximab differentiation SQUAMOUS-CELL CARCINOMA GROWTH-FACTOR RECEPTOR PLUS CETUXIMAB transcriptional activation vaccines INHIBITION internalization HER2 tyrosine proliferation transformation advanced colorectal-cancer LOCALLY ADVANCED HEAD KINASE-B BIOLOGY Her-2 METASTATIC COLORECTAL-CANCER SOLID TUMORS A431 monoclonal antibodies okadaic acid GENE-EXPRESSION PROTEIN-INTERACTION kinase inhibitor phase-i trial TYROSINE MECHANISM breast cancer fulvestrant-resistance erlotinib head and neck squamous cell cancer FTI resistance ERBB RECEPTORS transporter abcg2 TYROSINE KINASE MODEL in-vitro BREAST-CANCER MUTATIONAL ANALYSIS antibodies neu mutations PROTEIN-KINASE ABC transporter LOCALIZATION postmenopausal women androgen-independence progression GENE surface epithelial-cells colony-stimulating factor CETUXIMAB network growth-factor receptor gefitinib LYMPH-NODE METASTASES CARCINOMA breast-cancer PLUS KRAS MUTATION IN-VITRO zd1839 iressa pancreatic cancer Phase II ACQUIRED-RESISTANCE retention HUMAN TUMOR XENOGRAFTS DRUG-RESISTANCE receptor family open-label DNA-REPLICATION radionuclide SCATTER FACTOR multidrug-resistance signal-transduction SOMATIC MUTATIONS cancer organotypic culture farnesyl-protein transferase expression incessant ovulation ovary ARCHITECTURE NECK-CANCER ANTIBODY CETUXIMAB KERATINOCYTES VEGF monoclonal DOMAIN tumor-cells GROWTH FACTOR ANTIGEN PCNA COPY NUMBER protein lines resistant ovarian-cancer matrix metalloproteinase inhibitors BRAF antibody affibody molecule Oncology C-MET myeloid chemosensitivity ANAPLASTIC THYROID-CANCER matrix-metalloproteinase inhibitor POOR SURVIVAL LOT1 tyrosine phosphorylation DEPENDENT PROLIFERATION HETERODIMERIZATION PIK3CA GROWTH NETWORK epidermal growth factor SMALL-MOLECULE INHIBITOR TGF-alpha ACUTE MYELOID-LEUKEMIA CELL LUNG-CANCER monoclonal-antibody AKT PHASE-III TRIAL TYROSINE KINASE INHIBITORS INHIBITOR drug-resistance targeted therapy SIGNALING PATHWAY KINASE HEAD lapatinib radiation pure antiestrogen hormonally untreated prostate cancer first-line therapy breast cancer resistant protein spontaneous THERAPY
Last updated on Wednesday, February 05, 2020